BioNTech SE (BNTX) Stock Price & Analysis
BioNTech SE (BNTX) closed at USD 89.67 on Thursday, October 22, 2026, down 1.77% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 91.29; the Oct 22, 2026 session ranged USD 89.03–92.73 on volume of 1,164,434 shares. Market capitalization is $22.53B, with a 52-week range of USD 79.52–124 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BNTX.md
Key facts (BNTX)
- 1 of 80 tracked superinvestors hold BNTX (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 15 Form 4 filings, $89.8M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.29 on a 1–5 scale) (21 analysts), mean target USD 116.66 (range 76.03–144.05).
- Total return with dividends: 1Y -14.4% vs S&P 500 +14.9%; 5Y -67.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.76, revenue estimate $1.04B.
Superinvestors (SEC 13F-HR, Q2 2026) (BNTX)
1 of 80 tracked investors hold BNTX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Dodge & Cox Funds | Dodge & Cox | 0.18% | $342M | Added +0.0% |
Insider sales (SEC Form 4, open-market, last ~7 months) (BNTX)
15 of 15 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-08…2026-10-09 | Sahin Ugur | Chief Executive Officer | 63,209 | $5.9M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-10-07 | Sahin Ugur | Chief Executive Officer | 24,000 | $2.3M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-10-05…2026-10-06 | Sahin Ugur | Chief Executive Officer | 93,000 | $9.0M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-10-01…2026-10-02 | Sahin Ugur | Chief Executive Officer | 34,000 | $3.3M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-29…2026-09-30 | Sahin Ugur | Chief Executive Officer | 66,000 | $6.5M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-25…2026-09-28 | Sahin Ugur | Chief Executive Officer | 61,000 | $6.0M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-23…2026-09-24 | Sahin Ugur | Chief Executive Officer | 69,000 | $6.8M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-21…2026-09-22 | Sahin Ugur | Chief Executive Officer | 79,000 | $7.9M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-17…2026-09-18 | Sahin Ugur | Chief Executive Officer | 64,000 | $6.2M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-15…2026-09-16 | Sahin Ugur | Chief Executive Officer | 49,000 | $4.7M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-11…2026-09-14 | Sahin Ugur | Chief Executive Officer | 86,000 | $8.4M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-10 | Sahin Ugur | Chief Executive Officer | 20,500 | $2.0M | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-08…2026-09-09 | Sahin Ugur | Chief Executive Officer | 73,000 | $7.2M | 0.2% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-03…2026-09-04 | Sahin Ugur | Chief Executive Officer | 76,500 | $7.9M | 8.9% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-04-22 | Poetting Sierk | Chief Operating Officer | 50,000 | $5.5M | 11.1% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BNTX)
Consensus Buy (mean 2.29 on a 1–5 scale), 21 analysts; mean target USD 116.66 (low 76.03, high 144.05).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Canaccord Genuity | Target lowered | Buy | $136 → $132 |
| 2026-10-07 | Morgan Stanley | Target lowered | Overweight | $115 → $114 |
| 2026-09-08 | BMO Capital | Downgrade | Outperform → Market Perform | $128 → $105 |
| 2026-08-31 | Canaccord Genuity | Target lowered | Buy | $142 → $136 |
| 2026-08-05 | Citigroup | Target lowered | Buy | $130 → $125 |
| 2026-08-05 | Evercore ISI Group | Target lowered | Outperform | $135 → $130 |
| 2026-07-08 | Morgan Stanley | Target lowered | Overweight | $126 → $119 |
Total return (dividends reinvested) (BNTX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -14.4% | -67.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -14.4% | -20.0% |
| Volatility (annualized) | 46.7% | 52.2% |
| Max drawdown | -29.7% (Jan 2026→Mar 2026) | -76.7% (Nov 2021→Jul 2024) |
BNTX suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Manufacturing | “BioNTech iNeST Clinical Manufacturing (East Wing): We utilize our GMP-certified manufacturing facility at our” |
| Supplier | Nasdaq Stock Market | “Additionally, we rely on a provision in Nasdaq's Listed Company Manual that” |
| Partner | Pfizer (PFE) | “countries where it is commercializing our COVID-19 vaccine under our collaboration agreement with Pfizer for” |
| Partner | Therapeutics | “In April 2020, we entered into a Non-Exclusive License Agreement with Acuitas, or the Acuitas License” |
| Partner | REGENERON PHARMACEUTICALS, INC. (REGN) | “(10)In collaboration with Regeneron.” |
| Partner | Ganymed Pharmaceuticals | “Under the TRON License Agreement, we and Ganymed must agree on which party will have the primary role in” |
| Partner | Germany | “capabilities of our partners, except in Germany and Türkiye.” |
| Partner | Fosun Pharmaceutical Industrial Development | “Under our collaboration with Fosun Pharmaceutical Industrial Development, Co., Ltd, or Fosun Pharma, Fosun” |
| Partner | Siemens | “subsidiary, BioNTech RNA Pharmaceuticals GmbH, or BioNTech RNA, and Siemens announced a collaboration” |
| Partner | Ryvu Therapeutics | “prepayments for our collaborations with Ryvu Therapeutics S.A., Krakow, Poland, €5.5 million (€8.5 million as of” |
| Competitor | Moderna (MRNA) | “developed by Moderna, Inc. and Novavax, Inc. Our competitors pursuing vaccine candidates may have greater” |
Quoted from the company's 20-F filed Mar 10, 2026.
BNTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.76 | $0.66 | +15.4% | $1.04B | 5 |
| Next quarter (ends Dec 2026) | $-0.84 | $-0.84 | +0.2% | $516.4M | 5 |
| Current fiscal year (ends Dec 2026) | $-4.68 | $-4.26 | +9.9% | $1.78B | 10 |
| Next fiscal year (ends Dec 2027) | $-4.81 | $-4.33 | +11.2% | $1.80B | 10 |
BNTX options: expected move
Options price a move of about ±12.1% (±$11.08) by Nov 20, 2026, which includes earnings on Nov 3, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 53.1% | ±12.1% |
| Dec 18, 2026 | 56 | 49.2% | ±15.6% |
| Jan 15, 2027 | 84 | 47.9% | ±18.4% |
| Feb 19, 2027 | 119 | 46.8% | ±21.3% |
| Mar 19, 2027 | 147 | 47.6% | ±24.0% |
| May 21, 2027 | 210 | 47.6% | ±28.5% |
| Jun 17, 2027 | 237 | 46.4% | ±29.5% |
| Aug 20, 2027 | 301 | 46.8% | ±33.4% |
30-day implied volatility 53.6% vs 38.2% realized over the last 30 trading days. Put/call ratio (volume) 5.41. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:49 UTC)
| Price | USD 89.67 |
|---|---|
| Change | ▼ 1.77% (down) |
| Previous Close | USD 91.29 |
| Open | USD 90.75 |
| Day Range | USD 89.03 – 92.73 |
| 52-Week Range | USD 79.52 – 124 |
| Volume | 1,164,434 shares |
| Market Cap | $22.53B |
| Exchange | NMS |
Technical Analysis (BNTX)
Nexqual's technical model rates BNTX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.4 (neutral) |
| vs SMA50 | Below (USD 98.57) |
| MACD | -2.39 (negative) |
Analyst Ratings (BNTX)
Wall Street analysts rate BNTX "Buy" based on 21 analysts, with a mean price target of USD 116.66 (range USD 76.03–144.05), per Nexqual as of October 23, 2026 at 09:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 116.66 |
| High Target | USD 144.05 |
| Low Target | USD 76.03 |
| Buy / Hold / Sell | 14 / 7 / 0 |
Earnings (BNTX)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.76 |
| Revenue Estimate | $1.04B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -2.22 vs est -2.08 ▼ miss |
| 2026-03-31 | USD -1.95 vs est -1.92 ▼ miss |
| 2025-12-31 | USD -0.33 vs est -0.25 ▼ miss |
| 2025-09-30 | USD -0.12 vs est 0.1 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financials & Fundamentals (BNTX)
| Total Revenue | $2.65B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -59.50% |
| Gross Margin | +76.62% |
| Operating Margin | -806.63% |
| Profit Margin | -63.64% |
| ROE | -9.30% |
| Debt / Equity | 0.02 |
| Current Ratio | 7.85 |
| Total Cash | $13.46B |
| Total Debt | $316.10M |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Financial Health Score (BNTX)
Nexqual rates BioNTech SE's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:49 UTC.
| Growth | Mixed — Revenue +4.3% YoY (annual), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — EUR 13.5B cash vs EUR 316M debt, net cash position |
| Cash Flow | Solid — Operating cash flow EUR 680M (TTM) |
| Efficiency | Critical — ROE -9%, ROA -5.4% |
Ownership (BNTX)
| Insider Ownership | +57.19% |
|---|---|
| Institutional Ownership | +20.59% |
| Shares Outstanding | 251.20M |
| Float | 109.28M |
| Short % of Float | +3.74% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Leadership (BNTX)
BioNTech SE is led by Ugur Sahin, Co-Founder, CEO & Chair of the Management Board, per Nexqual as of October 23, 2026 at 09:49 UTC.
| Co-Founder, CEO & Chair of the Management Board | Ugur Sahin |
|---|---|
| CFO & Member of Management Board | Ramon Zapata-Gomez |
| MD, COO & Member of Management Board | Sierk Pötting |
| Senior Vice President of Global Financial Reporting & Accounting | Lisa Birringer |
| Vice President of Strategy & Investor Relations | Douglas Maffei |
Major Backers & Investors (BNTX)
Notable institutional backers of BioNTech SE include FMR, LLC, Fidelity, Primecap Management Company, according to Nexqual as of October 23, 2026 at 09:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 2.99% |
| Fidelity | 2.14% |
| Primecap Management Company | 1.49% |
| Dodge & Cox Inc. | 1.45% |
| Flossbach von Storch SE | 0.88% |
| T. Rowe Price | 0.82% |
| Temasek Holdings (Private) Ltd | 0.6% |
| BNP Paribas Financial Markets | 0.52% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.87% |
| BlackRock | 0.73% |
Source: Nexqual, October 23, 2026 at 09:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INCY | Incyte Corporation | USD 116.93 | ▲ 3.08% |
| GMAB | Genmab A/S | USD 40 | ▲ 1.09% |
| INSM | Insmed Incorporated | USD 95.06 | ▲ 1.08% |
| ROIV | Roivant Sciences Ltd. | USD 37.45 | ▲ 1.77% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 227.28 | ▲ 0.97% |
| EXEL | Exelixis, Inc. | USD 65.31 | ▲ 1.13% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt